Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | F10 | P00742 | 1/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.33 |
| ▸ | XIAP | P98170 | 2/20 | 0.33 |
| ▸ | BIRC3 | Q13489 | 2/20 | 0.33 |
| ▸ | BIRC2 | Q13490 | 2/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 8/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8001796 | 0.90 | F2 (0.33) | F2F10PRSS1XIAPBIRC3 | |
| SCHEMBL12820532 | 0.90 | MEN1 (0.36) | XIAPBIRC3BIRC2HDAC4HDAC1 | |
| SCHEMBL14201556 | 0.89 | SCN9A (0.31) | SCN9A | |
| SCHEMBL12820555 | 0.83 | HDAC4 (0.35) | XIAPBIRC3BIRC2HDAC4HDAC1 | |
| SCHEMBL8003495 | 0.82 | XIAP (0.32) | XIAPBIRC3BIRC2HDAC4HDAC1 | |
| SCHEMBL15849570 | 0.81 | PSMB9 (0.36) | HDAC1HDAC6 | |
| SCHEMBL12468417 | 0.81 | PSMB9 (0.36) | HDAC1HDAC6 | |
| SCHEMBL12467641 | 0.81 | PSMB9 (0.36) | HDAC1HDAC6 | |
| SCHEMBL13059576 | 0.81 | CTSB (0.41) | F2F10PRSS1GAA | |
| SCHEMBL8202772 | 0.81 | CTSB (0.41) | F2F10PRSS1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2003053349-A2 | INHIBITORS OF HEPATITIS C VIRUS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-03 | — | — | WO | disclosed |